Clinical Data
North Wales
About Clinical Data
Clinical Data, Inc. is focused on the development and commercialization of therapeutics, with two compounds in the areas of central nervous system and cardiovascular disorders. The Company's late-stage drug candidate is vilazodone, a dual-acting selective and potent serotonin reuptake inhibitor and serotonin receptor 1A (5-HT1A) partial agonist for the treatment of major depressive disorder (MDD). The Company's second late-stage drug candidate is apadenoson, trademarked Stedivaze, a selective adenosine receptor 2A (AR2A) agonist and coronary vasodilator in Phase III of clinical development for use in nuclear Single Photo Emission Computed Topography (SPECT) myocardial perfusion imaging. The Company also provides the FAMILION family of genetic tests for inherited cardiac syndromes, including cardiac channelopathies and cardiomyopathies. On September 30, 2009, the Company purchased all the assets of Epix Pharmaceuticals, Inc. (Epix).
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $259.6K
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2011)
- Ticker: nasdaq:CLDA
- Website: clda.com
- Phone: 617-527-9933
Industries & Categories
Biotechnology, Developer Platform, Genetics
Canonical: https://fsome.com/organization/clinical-data-1650039 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.